These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 25934535)

  • 1. Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature.
    Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
    Urol Oncol; 2015 Apr; 33(4):171-8. PubMed ID: 25934535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.
    Bjarnason GA; Khalil B; Hudson JM; Williams R; Milot LM; Atri M; Kiss A; Burns PN
    Urol Oncol; 2014 May; 32(4):480-7. PubMed ID: 24321258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma.
    Zhu X; Zhang X; Sun G; Liu Z; Zhang H; Yang Y; Ni Y; Dai J; Zhu S; Chen J; Zhao J; Wang Z; Zeng H; Shen P
    Cancer Manag Res; 2021; 13():6833-6845. PubMed ID: 34512023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?
    Bjarnason GA
    Can Urol Assoc J; 2016; 10(11-12Suppl7):S252-S255. PubMed ID: 28096939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Focus on the occurrence, diagnosis and individualized treatment of tumors after renal transplantation].
    Chen DJ; Chen JH
    Zhonghua Yi Xue Za Zhi; 2019 Mar; 99(10):725-727. PubMed ID: 30884622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
    Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
    Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis.
    Hess G; Coiffier B; Crump M; Gisselbrecht C; Offner F; Romaguera J; Kang L; Moran PJ
    Exp Hematol Oncol; 2015; 4():11. PubMed ID: 25938001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].
    Trump D
    Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study.
    Qin S; Bi F; Jin J; Cheng Y; Guo J; Ren X; Huang Y; Tarazi J; Tang J; Chen C; Kim S; Ye D
    Onco Targets Ther; 2015; 8():1363-73. PubMed ID: 26089686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Hawkins RE; Crinò L; Kim TM; Carteni G; Eberhardt WE; Zhang K; Fly K; Matczak E; Lechuga MJ; Hariharan S; Bukowski R
    Br J Cancer; 2015 Jun; 113(1):12-9. PubMed ID: 26086878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
    Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
    Int J Breast Cancer; 2015; 2015():240750. PubMed ID: 26078883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.
    Régnier SA; Malcolm W; Haig J; Xue W
    Clinicoecon Outcomes Res; 2015; 7():235-47. PubMed ID: 25999748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib.
    Niu FY; Wu YL
    Onco Targets Ther; 2015; 8():999-1007. PubMed ID: 25999733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
    Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
    Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel, capecitabine and concurrent radiotherapy for gastric cancer patients with postoperative locoregional recurrence.
    Xie J; Liang N; Qiao L; Su L; Li K; Luo H; Zhang J; Zhang J
    Tumori; 2015; 101(4):433-9. PubMed ID: 25983095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.
    Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Ishidao T; Nagasaki E; Homma S
    Oncol Rep; 2015 Jul; 34(1):504-10. PubMed ID: 25976081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ; Chao YM; Liu NC; Chan JY
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells.
    Mei JZ; Liu GJ; Zhang XJ; Zhao JZ; Feng RT
    Genet Mol Res; 2015 Apr; 14(2):3082-9. PubMed ID: 25966072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.